Clinical burden of late-onset, clinically significant CMV infection beyond 100 days in allo-HSCT patients after letermovir prophylaxis
This study demonstrates the great burden of late-onset cs-CMVi in patients after allo-HSCT. Extended LET prophylaxis beyond 100 days post-transplant may benefit especially those at high risk of cs-CMVi.
Authors
- Junko Hattori (ORCID: https://orcid.org/0000-0001-9848-5816)
- Rika Ohkubo (ORCID: https://orcid.org/0009-0002-1529-9642)
Institutions
- MSD K.K. (Japan) (JP)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1080/03007995.2025.2470733
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- MSD K.K.